Plexpress Announces Collaboration with Admescope
News May 17, 2012
Plexpress has announced a new collaboration with the contract research organisation (CRO), Admescope, which will now include TRAC as part of its services for investigating in vitro drug interactions and pre-clinical ADME-Tox responses.
Admescope customers can now take advantage of the benefits offered by Plexpress’ novel TRAC (Transcript Analysis with the aid of Affinity Capture) technology.
These include higher sample throughput, increased assay speed and reduced technical variation when compared to similar gene expression analyses undertaken using qPCR or microarrays.
In the first instance, Admescope will offer Plexpress’ well-validated multiplex assays targeting the Cytochrome P450 (CYP) family, which can be used as an insightful indicator of potential drug toxicity and efficacy.
The new service is particularly well suited to meeting recent draft recommendations from the FDA, which suggest that CYP mRNA analysis might be more informative for drug metabolism studies than measuring CYP activity.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE